Speaker articles
Take a look at what some of The cancer-immunity cycle speakers have published recently and chat with them about their work in Sitges, Spain.
Keynote Speakers
Ira Mellman, Genentech, USA
The cancer-immunity cycle: Indication, genotype, and immunotype
Carl June, University of Pennsylvania, USA
CAR T cell combination therapies to treat cancer
Speakers
Sebastian Amigorena, Institut Curie, France
SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
George Coukos, Lausanne University Hospital, Switzerland
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma
Catherine Fridman, Centre de Recherche des Cordeliers, France
Tertiary lymphoid structures and B cells: An intratumoral immunity cycle
Jon Kagan, Harvard Medical School, USA
Correction of age-associated defects in dendritic cells enables CD4+ T cells to eradicate tumors
Marleen Kok, Netherlands Cancer Institute, Netherlands
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Laura Mackay, The University of Melbourne, Australia
Retinoic acid and TGF-β orchestrate organ-specific programs of tissue residency
Erika Pearce, John Hopkins Medicine, USA
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity
Filipe Pereira, Lund University, Sweden
In vivo dendritic cell reprogramming for cancer immunotherapy
Mikael Pittet, University of Geneva, Switzerland
A neutrophil response linked to tumor control in immunotherapy
Yardena Samuels, Weizmann Institute of Science, Israel
Translation dysregulation in cancer as a source for targetable antigens
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
Josep Tabernero, Vall d’Hebron Institute of Oncology (VHIO), Spain
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Shannon Turley, Genentech, USA
Systematic perturbation screens identify regulators of inflammatory macrophage states and a role for TNF mRNA m6A modification
Karin de Visser, Netherlands Cancer Institute, Netherlands
Kai Wucherpfennig, Dana-Farber Cancer Institute, USA
Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies
Zemin Zhang, Peking University, China
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer